Most of the U.S. Department of Justice’s major pharma-related decisions invoking the False Claims Act recently have involved illegal marketing and sales. So far, GSK’s is the only one to deal with current good manufacturing practices (cGMP’s). Read on for a roundup of the top 20 recent cases from Taxpayers Against Fraud (TAF).
From
'On Pharma'
